Kornimate/medical-research-clean huggingface dataset:
biologic mechanisms of early exercise after intracerebral hemorrhage

Conditions: Intracerebral Hemorrhage; Acute Ischemic Stroke

Summary: this study aims to determine whether in-bed cycle ergometry, early in the hospital course after a brain hemorrhage could balance damaging and reparative inflammation in the brain. inflammatory factors of two groups of patients with brain hemorrhage will be compared, one group will receive in-bed cycling beginning 3 days after hemorrhage plus usual care and the other group will receive usual care only.


Eligibility criteria:
inclusion criteria: * supratentorial intracerebral hemorrhage with or without intraventricular hemorrhage * pre-morbid modified rankin score of 0-2 * patient must be able to provide informed consent or have a legally authorized representative to provide consent on patient's behalf exclusion criteria: * patients with known inflammatory conditions, infection requiring antibiotics or pregnancy * patients receiving daily anti-inflammatory medications including but not limited to prednisone, methotrexate, non-steroidal anti-inflammatory medications (ibuprofen, naproxen, indomethacin, celecoxib) and aspirin \>325mg * glasgow coma score (gcs) 3 48 hours after admission * patients in whom withdrawal of life support is being considered by surrogate decision makers * injury to the lower extremities, hips or pelvis, weight \>250 kg (weight limit of cycle), or body habitus precluding normal function of cycle

Keywords: rehabilitation cycle ergometry
istradefylline for parkinson disease with cognitive impairment

Conditions: Parkinson Disease; Cognitive Impairment

Summary: the purpose of this research study is to determine whether istradefylline improves cognition in individuals with parkinson disease with cognitive impairment.

istradefylline has been approved by the u. s. food and drug administration (fda) to reduce "off" episodes in parkinson disease. the period when levodopa has a positive effect on parkinson's symptoms is called on-time. once the medication stops working, a so called "off" episode starts, where symptoms recur. usual care for treatment of parkinson disease with cognitive impairment is use of cognition enhancing medications also called cholinesterase inhibitors. in this study, participants will receive usual care, and in addition, they will be asked to take istradefylline daily for 26 weeks.

Eligibility criteria:
inclusion criteria: * meet criteria for probable parkinson disease dementia or pd-mci (mild cognitive impairment) * age greater than 50 * hoehn and yahr stage \< 4 in "on" state * currently taking carbidopa/levodopa * antiparkinsonian medications stable for at least 4 weeks prior to baseline visit * cholinesterase inhibitor dose stable for 8 weeks prior to baseline visit exclusion criteria: * meet criteria for dementia with lewy bodies, including dementia onset prior to or within 1 year of parkinsonism onset * presence of troublesome dyskinesias * pregnancy or possibility of becoming pregnant during the study period. * moderate or severe hepatic impairment * dementia too severe to complete study measures or to adhere to medication schedule
mayo clinic ibd biobank

Conditions: Inflammatory Bowel Diseases

Summary: researchers are collecting and storing blood, stool, and urine samples and medical information to better understand inflammatory bowel disease (ibd) to improve disease outcome.

subjects will be sent a letter detailing the proposed biobank and soliciting enrollment. following the informed consent process, subjects will provide a blood sample (50 ml), urine sample (50 ml), and stool. the blood and urine samples will either be collected at the one of the mayo clinic outpatient laboratories or by a mail-out kit. subjects will be asked to complete a questionnaire and 24-hour food recall questionnaire (completed online).

Eligibility criteria:
inclusion criteria: * patients diagnosed with inflammatory bowel disease (ibd) who are between the ages of 18 and 85 at time of study enrollment. * the diagnosis of ibd will be based on the standard ibd criteria including biochemical and colonoscopy screening. * women with inflammatory bowel disease of childbearing potential and pregnant women will be offered enrollment because there is no risk to an unborn child in this investigation. * patients between the ages of 18 and 85 without history of ibd or colon cancer. exclusion criteria: * patients with known liver disease. * patients unable to provide informed consent. * prisoners and institutionalized individuals. * patients with a history of colorectal cancer.

Keywords: ibd ulcerative colitis crohn's
study to evaluate the efficacy and safety of tel/aml/ctd in elderly patients with essential hypertension

Conditions: Essential Hypertension

Summary: this study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with telmisartan, amlodipine, and chlorthalidone fixed-dose combination.

this is a phase iv, open-label, prospective, long-term cohort, observational study to identify the predictive model of cardiocerebrovascular risk factors in elderly patients with more than three antihypertensive agents in patients with essential hypertension in korea.

Eligibility criteria:
inclusion criteria: 1. a patient over 65-year-old with essential hypertension 2. a patient with essential hypertension who require treatment with 3 or more antihypertensive medication, as determined by investigator's decision 3. a patient with no macce within 6 months prior to the enrollment 4. a patient who voluntarily signed the informed consent form exclusion criteria: 1. a patient who participates in clinical trial 2. a patient who are contraindicated for the truset tablet according to the label. 3. a patient who is unable to complete the study judged by the investigator.

Keywords: telmisartan/amlodipine/chlorthalidone fixed-dose combination (truset)
impact of low dose fluoroscopy in ureteroscopy

Conditions: Ureteral Stone

Summary: one of the most effective strategies to decrease radiation exposure during ureteroscopy is to use low dose. however, the quality of the image obtained is inferior to full dose image. the main concern is to maintain the stone free and complication rate despite the inferior quality of image obtained. our aim was to evaluate if reducing the dose of fluoroscopy to ¼ instead of full dose would impact in a reduction of total radiation exposure despite a possible increase in fluoroscopy time. also, if this strategy would impact in operation time, stone free rate and complication rate of unilateral semi-rigid ureteroscopy for ureteral stone treatment due too less than optimal fluoroscopy image. all patients over 18 years old diagnosed with ureteral stone from 5 mm to 20 mm in diameter by ct scan were counseled regarding their treatment options. patients who failed spontaneous passage or medical treatment or chose endourologic treatment were included in this study. patients with abnormal urinary anatomy such as horseshoe kidney, pelvic kidney or duplex system were excluded from the study.

several studies support an association between increasing cancer risk with increasing exposure to radiation. typical radiation exposure for a patient submitted to ureteroscopy ranges from 2.5 to 100 msv. the international commission on radiological protection recommends an annual occupational radiation exposure limit of no more than 50 msv per year. one of the most effective strategies to decrease radiation exposure during ureteroscopy is to use low dose. however, the quality of the image obtained is inferior to full dose image. the main concern is to maintain the stone free and complication rate despite the inferior quality of image obtained. our aim was to evaluate if reducing the dose of fluoroscopy to ¼ instead of full dose would impact in a reduction of total radiation exposure despite a possible increase in fluoroscopy time. also, if this strategy would impact in operation time, stone free rate and complication rate of unilateral semi-rigid ureteroscopy for ureteral stone treatment due too less than optimal fluoroscopy image. all patients over 18 years old diagnosed with ureteral stone from 5 mm to 20 mm in diameter by ct scan were counseled regarding their treatment options. patients who failed spontaneous passage or medical treatment or chose endourologic treatment were included in this study. patients with abnormal urinary anatomy such as horseshoe kidney, pelvic kidney or duplex system were excluded from the study.

Eligibility criteria:
inclusion criteria: * ureteral stone from 5 mm to 20 mm in diameter by ct scan exclusion criteria: * abnormal urinary anatomy such as horseshoe kidney, pelvic kidney or duplex system

Keywords: urolithiasis fluoroscopy radiation ureteroscopy
duration of urinary catheterization following cesarean deliveries under neuraxial anesthesia

Conditions: Cesarean Delivery; Urinary Catheterization

Summary: in cesarean deliveries, urinary catheters are often used to help empty the bladder while patients have limited mobility. these catheters typically stay in during early recovery because certain pain medications can make it hard for patients to urinate. recently, the society of obstetric anesthesia and perinatology (soap) recommended removing catheters within 6-12 hours after delivery to aid recovery. however, at bc women's hospital, a review found that catheters stayed in for an average of 19 to 19.4 hours, even when patients were mobile. leaving catheters in too long can increase the risk of urinary tract infections (utis), pain, and urination issues, which can delay recovery and extend hospital stays. an internal review showed that factors like patient anxiety may affect when catheters are removed. postpartum anxiety affects around 9.9% to 20.7% of new mothers in the first year and is an important factor in recovery after a cesarean delivery. the main goal of this study is to look at how long urinary catheters stay in patients who had a cesarean delivery under spinal or epidural anesthesia, and what the score is from a questionnaire used to measure anxiety called the state trait anxiety inventory (stai-s), to see if there is a link between them.

this study aims to analyze how long foley catheters stay in the patient after their cesarean delivery under neuraxial anesthesia and what barriers there are in taking them out earlier.

Eligibility criteria:
inclusion criteria: * patients ≥19 years of age. * undergoing cesarean delivery (elective or emergent) at bc women's hospital. * neuraxial anesthesia as their primary mode of anesthesia (spinal, epidural, combined spinal-epidural, dural-puncture epidural). * in-patient status at 24 (+/- 8) hours. * self-reported proficiency in speaking and reading english. exclusion criteria: * refusal to participate. * inability to provide informed consent. * other surgery (i.e. cervical cerclage) or delivery modes (i.e. operative vaginal delivery). * de novo general anesthetic, or patients who had a conversion from neuraxial to a general anesthetic. * communication from patient's nurse indicating that it is not appropriate to approach due to distressing birth experience and/or outcome.

Keywords: patient recovery cesarean delivery urinary catheterization foley catheter patient anxiety
abscopal effect of radiotherapy in combination with rhgm-csf for advanced thymic epithelial tumours

Conditions: Thymoma

Summary: the purpose of this study is to determine whether radiotherapy (rt) combined with recombined human granulocyte-macrophage colony stimulating factor(rhgm-csf) is safe, effective in the treatment of patients with advanced thymic epithelial tumours.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years; 2. histologically proven thymic epithelial tumours； 3. stage iv according to uicc stage system(version 8,2017), at least with two evaluable abscopal lesions (≥1cm)（excluding intestinal metastasis）; 4. evaluated as effective or stable disease after first-line chemotherapy or progressed after second-line chemotherapy (progression sites were no more than three sites); 5. ecog performance status: 0-1; 6. life expectancy ≥ 3 months. 7. adequate baseline organ and marrow function: absolute neutrophil count greater than 1500 cells per μl, platelet concentration of greater than 50 000 per μl, total bilirubin less than 1•5 times the upper limit of normal (uln), aspartate aminotransferase and alanine aminotransferase less than 2•5 times the uln, and serum creatinine less than 1•5 times the uln; 8. female subjects have a negative urine or serum pregnancy test within 1 week prior to treatment if of childbearing potential; 9. asymptomatic subjects with brain metastasis can be included, but the sites of brain cannot be considered as target sites; 10. asymptomatic subjects with bone metastasis can be included, but the sites of bone cannot be considered as target sites. exclusion criteria: 1. having received immunotherapy within 4 weeks prior to inclusion; 2. allergic to gm-csf, inf-α2b or diagnosed with immune system disease, receiving immunosuppressant, such as prednisone, dexamethasone, methylprednisolone, methotrexate, hydroxychloroquine, cyclophosphamide, azathioprine and so one; 3. receiving treatment of other trials; 4. any unstable systemic disease, including active infection, symptomatic congestive heart failure,myocardial infarction onset six months before included into the group, unstable angina, and severe arrhythmia, uncontrolled chronic lung disease; 5. unwilling to sign consent; 6. women in pregnancy or lactation;
nova22007 0.05% and 0.1% cyclosporine versus vehicle for the treatment of dry eye

Conditions: Dry Eye

Summary: study is to assess the safety and efficacy of nova22007 0.05% and 0.1% cyclosporine ophthalmic cationic emulsions qd compared to vehicle for the treatment of the signs and symptoms of dry eye after a 3 month treatment period.


Eligibility criteria:
inclusion criteria: * male and female 18 years and older * diagnosis of dry eye in both eyes exclusion criteria: * contraindications to the use of the study medications * known allergy or sensitivity to the study medications or their components * female currently pregnant, nursing, or planning a pregnancy; or woman who has a positive pregnancy test * have participated in an investigational drug or device study within 30 days of visit 1

Keywords: dry eye cyclosporine
a study of pain relief in low back pain

Conditions: Chronic Low Back Pain

Summary: this is a study of the safety and pain-relieving ability of extended release hydrocodone and acetaminophen tablets in patients with moderate to severe low back pain


Eligibility criteria:
inclusion criteria: * males and females, ages 21-75 years * if female, must be of non-child bearing potential or practicing birth control * has a history of chronic low back pain for at least 6 months * requires medication for the management of the chronic low back pain * has sufficient pain to justify the use of around-the-clock opioids exclusion criteria: * is associated with any currently ongoing research study, or has previously participated in a vicodin cr study * is allergic or has had a serious reaction to hydrocodone, other opioids, or acetaminophen * cannot discontinue pain medications, even for the short time prior to the study start * has any clinically significant illness or recent injury, or has any significant laboratory abnormality, or has recently had major surgery, or plans to have surgery * has a history of gastric bypass surgery or preexisting gastrointestinal narrowing, or history of diseases that may narrow the gastrointestinal tract * has a history of malnutrition or starvation * has a history of drug (licit or illicit) or alcohol abuse or addiction, or consumes more than 4 alcoholic drinks per day * has a history of a major depressive episode within the past 2 years, or requires treatment with certain drugs for depression, or has a history of major psychiatric disorder * is a pregnant or breastfeeding woman * is incapacitated, bedridden, or confined to a wheelchair * has initiated any new therapy or medication for chronic low back pain within 1 month of screening * has had surgery, certain types of low back procedures, injured, or received certain medications for chronic low back pain within a certain specified time frame * has back pain due to or associated with certain types of conditions * has other conditions that may cause pain, such as rheumatoid arthritis, gout, or fibromyalgia
predictability of preoperative hemoglobin a1c in diabetic patients underwent off-pump coronary artery bypass surgery: a retrospective study.

Conditions: Coronary Artery Disease, Diabetes

Summary: the aim of this study is to evaluate evaluated the impact of preoperative hba1c in diabetic patients on perioperative glycemic variability and outcome after off-pump coronary artery bypass (opcab). the medical records of patients who had a preoperative diagnosis of diabetes and underwent opcab from 2005 to 2017 will be reviewed. patients are divided by hba1c levels (\<7.0% or ≥7.0%). glycemic variability during surgery and up to 24 hours after surgery is assessed by the coefficient of variation. the primary outcome is defined as a composite of postoperative permanent stroke, prolonged ventilation, deep sternal wound infection, renal failure, reoperation, mortality according to the definition of sts (society of thoracic surgery) version 2.81 adult cardiac surgery database. if one or more of the above five morbidity or mortality occur, it is assumed that composite morbidity/mortality had occurred. we compare postoperative complications, mortality and perioperative glycemic variability between patients with hba1c ≥7.0% and \<7.0%, and examined the effects of perioperative glycemic control on postoperative morbidity and mortality (composite morbidity/mortality).


Eligibility criteria:
inclusion criteria: * patients with a history of preoperative diabetes mellitus and with available results of hba1c test within 3 months before surgery. * patients who aged 20 to 89 years exclusion criteria: * patient who had a history of previous coronary artery bypass surgery * patients whose surgery plan changed to cardiopulmonary bypass during surgery.
invasive left heart catheterization registry

Conditions: Heart Failure With Preserved Ejection Fraction; Left Ventricular Diastolic Dysfunction

Summary: retrospectively enrolled suspicious of heart failure with preserved ejection fraction (hfpef) patients who underwent left heart catheterization with the measurement of left ventricular end-diastolic pressure.

heart failure (hf) with preserved ejection fraction (hfpef) remains a poorly understood clinical syndrome without effective targeted therapies. the clinical syndrome of hfpef develops from a complex interaction of several risk factors such as aging, obesity, hypertension, myocardial ischemia, and arterial stiffness that cause organ dysfunction and, ultimately, clinical symptoms. although the h2fpef and hfa-peff scores have recently been proposed to estimate the probability of hfpef in patients suffering from unexplained dyspnea, diagnosing hfpef remains still challenging. the aim of the current registry was to evaluate the role of invasive left heart catheterization with the measurement of left ventricular end-diastolic pressure (lvedp) in suspicious of hfpef patients.

Eligibility criteria:
inclusion criteria: * left ventricular ejection fraction \> 50% * patients who had a symptom and/or signs of heart failure (dyspnea on exertion, chest discomfort, fatigue, dizziness, or ankle edema) * patients who underwent left heart catheterization with the measurement of left ventricular end-diastolic pressure exclusion criteria: * left ventricular ejection fraction \<50% * acute coronary syndrome * more than moderate valvular heart disease * primary cardiomyopathies such as dilated cardiomyopathy and hypertrophic cardiomyopathy, amyloidosis * pulmonary arterial hypertension * heart transplantation * constrictive pericarditis * stress-induced cardiomyopathy

Keywords: heart failure with preserved ejection fraction left ventricular end diastolic pressure echocardiography
the effectiveness of bupivacaine and bupivacaine+dexmedetomidine combination in transversus abdominis plane* block

Conditions: Colorectal Cancer; Colorectal Neoplasms

Summary: transversus abdominis plane (tap) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. thus, tap block is widely implemented in perioperative management of colorectal cancer patients. researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the tap block applied in colorectal cancer surgeries.

transversus abdominis plane (tap) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. with the increasing use of ultrasound guidance during peripheral nerve blocks, trunk blocks such as the transversus abdominis plane (tap) block are widely used for analgesia after abdominal surgery. the advantages of tap block include being less invasive than epidural analgesia, lower incidence of hypotension, and shorter hospital stay. due to these advantages, tap block has become a widely preferred method. researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the tap block applied in colorectal cancer surgeries. the study will be conducted in a tertiary oncology hospital in turkey and 84 colorectal cancer patients will be included.

Eligibility criteria:
inclusion criteria: * colorectal cancer diagnosis * undergoing colorectal cancer surgery exclusion criteria: * allergic reaction to local anesthetics * bleeding anomalies * infection in tap block area

Keywords: colorectal cancer colorectal cancer surgery colorectal neoplasym transversus abdominis plane transversus abdominis plane block